Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean category antidepressive agent an group approved?
Displaying drugs 451 - 475 of 10443 in total

Budesonide

Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product...
Approved
Matched Categories: … Corticosteroids, Potent (Group III) ... Autonomic Agents ... Anti-Asthmatic Agents ... Bronchodilator Agents ... Anti-Inflammatory Agents …

Sulesomab

Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
Approved

Human botulinum neurotoxin A/B immune globulin

Infant botulism is a rare infectious disease occurring in infants in which Clostridium botulinum colonize the large intestine and being to produce botulinum neurotoxin directly in the gut. As these neurotoxins interfere with cholinergic nervous transmission, patients initially present with evident of loss of muscle tone (e.g. constipation, ptosis, feeding...
Approved
Matched Description: … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in …

Gestrinone

Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and is used primarily in the treatment of endometriosis. Gestrinone was developed in the early 1970s and was tested clinically as...
Approved
Matched Description: … Gestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group …
Matched Categories: … Contraceptive Agents, Female ... Contraceptive Agents, Hormonal ... Reproductive Control Agents ... Antigonadotropins and Similar Agents …

Pramipexole

Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is...
Approved
Investigational
Matched Description: … It was first approved by the FDA in 1997 [L5882]. ... This increase may be attributed to an aging population along with other contributing factors [A176861 ... In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA …
Matched Categories: … Dopamine Agents ... Anti-Dyskinesia Agents ... Hypotensive Agents ... Neurotransmitter Agents ... Central Nervous System Agents …

Moroctocog alfa

Moroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is a recombinant DNA-based drug with functional characteristics comparable to those of endogenous coagulation Factor VIII, the essential human blood clotting protein that is impaired in Hemophilia A. Moroctocog alfa is identical in sequence to endogenously produced Factor...
Approved
Matched Description: … Moroctocog alfa is approved by Health Canada and by the European Medicines Agency for the control and ... Unfortunately, purification of protein from human plasma carries an increased risk of transmission of ... and B-subunits, and [DB11607], which is a fully recombinant factor VIII-Fc fusion protein which has an …

Phenoxymethylpenicillin

Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by...
Approved
Vet approved
Matched Description: … has been suggested by the American Heart Association and the American Dental Association for use as an ... An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections ... dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an …
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents …

Ruxolitinib

Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by...
Approved
Matched Description: … [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate ... Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor ... [A229938] Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by …
Matched Categories: … Antineoplastic Agents ... Myelosuppressive Agents ... Immunosuppressive Agents ... Antineoplastic and Immunomodulating Agents ... Agents for Dermatitis, Excluding Corticosteroids …

Trovafloxacin

Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective...
Approved
Investigational
Withdrawn
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents ... QTc Prolonging Agents ... Photosensitizing Agents ... Highest Risk QTc-Prolonging Agents …

Denosumab

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy...
Approved
Matched Description: … [A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis ... It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss …
Matched Categories: … Immunosuppressive Agents ... Bone Density Conservation Agents …

Larotrectinib

Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Matched Description: … It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847] ... Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine ... kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important …
Matched Categories: … Antineoplastic Agents ... Antineoplastic and Immunomodulating Agents …

Oxolamine

Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant . It is listed as a prescription drug in New Zealand legislation . Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation .
Approved
Matched Description: … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422]. ... Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant …
Matched Categories: … Antitussive Agents ... Respiratory System Agents ... Central Nervous System Agents …

Neisseria meningitidis serogroup b nhba fusion protein antigen

Approved

Neisseria meningitidis serogroup b nada protein antigen

Approved

Ceftazidime

Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis,...
Approved
Matched Description: … [L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone …
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents ... Nephrotoxic agents …

Cefixime

Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis,...
Approved
Investigational
Matched Description: … [A263031] Cefixime was first approved in the United States in 1986.[L49293] ... [A232920, A232925, A232930] Cefixime is a broad-spectrum antibiotic and an orally-active third-generation …
Matched Categories: … Anti-Bacterial Agents ... Anti-Infective Agents …

Faricimab

Retinal vascular diseases (RVDs) such as diabetic macular edema (DME), age-related macular degeneration (AMD), and retinal vein occlusion (RVO) are typically caused by retinal ischemia and subsequent neovascularization (NV).[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies...
Approved
Investigational
Matched Description: … [A225985, A225990, A225995] Faricimab is an IgG1-derived bispecific antibody capable of simultaneously ... [A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January ... Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved …
Matched Categories: … Angiogenesis Modulating Agents ... Antineovascularisation Agents ... Ocular Vascular Disorder Agents …

Zopiclone

Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Approved
Matched Categories: … Photosensitizing Agents ... Central Nervous System Agents ... Methemoglobinemia Associated Agents …

Propiolactone

Propiolactone is a lactone compound with a four-membered ring. It is a colorless liquid with a pungent slightly sweet odor. Propiolactone is a disinfectant used for the sterilization of blood plasma, vaccines, tissue grafts, surgical instruments, and enzymes. It has been used against bacteria, fungi, and virus. It is currently...
Approved
Withdrawn
Matched Description: … [A32144] It is currently FDA approved for its use as an indirect additive used in food contact substances …
Matched Categories: … Anti-Infective Agents …

Zilucoplan

Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of...
Approved
Matched Description: … [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same …
Matched Categories: … Immunosuppressive Agents ... Complement Inactivating Agents ... Antineoplastic and Immunomodulating Agents …

Memantine

Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's...
Approved
Investigational
Matched Description: … Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist …
Matched Categories: … Dopamine Agents ... Anti-Dyskinesia Agents ... Neurotransmitter Agents ... Central Nervous System Agents ... Miscellaneous Central Nervous System Agents …

Gamolenic acid

Gamolenic acid, or gamma-linolenic acid (γ-Linolenic acid) or GLA, is an essential fatty acid (EFA) comprised of 18 carbon atoms with three double bonds that is most commonly found in human milk and other botanical sources . It is an omega-6 polyunsaturated fatty acid (PUFA) also referred to as 18:3n-6;...
Approved
Investigational
Matched Description: … Gamolenic acid, or gamma-linolenic acid (γ-Linolenic acid) or GLA, is an essential fatty acid (EFA) comprised ... It is an omega-6 polyunsaturated fatty acid (PUFA) also referred to as 18:3n-6; 6,9,12-octadecatrienoic …
Matched Categories: … Agents that reduce seizure threshold …

Triamcinolone

Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more...
Approved
Vet approved
Matched Description: … [L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection …
Matched Categories: … Corticosteroids, Moderately Potent (Group II) ... Anti-Inflammatory Agents ... Agents Causing Muscle Toxicity ... Agents to Treat Airway Disease ... Immunosuppressive Agents …

Almotriptan

Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that...
Approved
Investigational
Matched Categories: … Antidepressive Agents ... Serotonin Agents ... Agents that produce hypertension ... Neurotransmitter Agents …

Avalglucosidase alfa

Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. In Pompe disease, the...
Approved
Investigational
Matched Description: … GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. ... [L39205] The EMA approved the drug on June 24, 2022.[L42720] ... [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of …
Displaying drugs 451 - 475 of 10443 in total